306937-35-9 Usage
Derivative of acetamide
A compound that is structurally related to acetamide, with modifications to its chemical structure, in this case, the addition of a phenyl ring with chlorine and fluorine substituents.
Phenyl ring
A benzene ring, a six-carbon ring with alternating single and double bonds, which is a fundamental structure in many organic compounds.
Chlorine and fluorine substituents
Chlorine and fluorine atoms attached to the phenyl ring, which modify the chemical properties of the compound and contribute to its potential biological activity.
Pharmaceutical industry use
The compound is commonly used in the pharmaceutical industry due to its potential biological activity, which may lead to the development of new drugs or therapies.
Intermediate in synthesis
2-(2-chloro-4-fluorophenyl)acetamide can be used as a starting material or intermediate in the synthesis of other organic and medicinal compounds, making it a valuable building block in chemical reactions.
Safety precautions
It is important to handle this chemical with care and follow safety guidelines, as it may pose health and environmental risks if not properly managed. This includes using appropriate personal protective equipment and disposing of the compound according to regulations.
Check Digit Verification of cas no
The CAS Registry Mumber 306937-35-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,6,9,3 and 7 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 306937-35:
(8*3)+(7*0)+(6*6)+(5*9)+(4*3)+(3*7)+(2*3)+(1*5)=149
149 % 10 = 9
So 306937-35-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H7ClFNO/c9-7-4-6(10)2-1-5(7)3-8(11)12/h1-2,4H,3H2,(H2,11,12)
306937-35-9Relevant academic research and scientific papers
Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor
Jung, Hui Jin,Nam, Eun Hye,Park, Jin Young,Ghosh, Prithwish,Kim, In Su
supporting information, (2021/02/26)
Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.
